195 related articles for article (PubMed ID: 17187405)
1. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.
Becker G; Allgaier HP; Olschewski M; Zähringer A; Blum HE;
Hepatology; 2007 Jan; 45(1):9-15. PubMed ID: 17187405
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
Barbare JC; Bouché O; Bonnetain F; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Cattan S; Lemoine A; Blanc JF; Bronowicki JP; Zarski JP; Cazorla S; Gargot D; Thevenot T; Diaz E; Bastie A; Aparicio T; Bedenne L
Eur J Cancer; 2009 Jul; 45(10):1788-97. PubMed ID: 19303768
[TBL] [Abstract][Full Text] [Related]
3. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.
Yuen MF; Poon RT; Lai CL; Fan ST; Lo CM; Wong KW; Wong WM; Wong BC
Hepatology; 2002 Sep; 36(3):687-91. PubMed ID: 12198662
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.
Cebon J; Findlay M; Hargreaves C; Stockler M; Thompson P; Boyer M; Roberts S; Poon A; Scott AM; Kalff V; Garas G; Dowling A; Crawford D; Ring J; Basser R; Strickland A; Macdonald G; Green M; Nowak A; Dickman B; Dhillon H; Gebski V;
Br J Cancer; 2006 Oct; 95(7):853-61. PubMed ID: 16953241
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide.
Rabe C; Pilz T; Allgaier HP; Halm U; Strasser C; Wettstein M; Sauerbruch T; Caselmann WH
Z Gastroenterol; 2002 Jun; 40(6):395-400. PubMed ID: 12055662
[TBL] [Abstract][Full Text] [Related]
6. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Rinke A; Müller HH; Schade-Brittinger C; Klose KJ; Barth P; Wied M; Mayer C; Aminossadati B; Pape UF; Bläker M; Harder J; Arnold C; Gress T; Arnold R;
J Clin Oncol; 2009 Oct; 27(28):4656-63. PubMed ID: 19704057
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.
Verset G; Verslype C; Reynaert H; Borbath I; Langlet P; Vandebroek A; Peeters M; Houbiers G; Francque S; Arvanitakis M; Van Laethem JL
Br J Cancer; 2007 Sep; 97(5):582-8. PubMed ID: 17687341
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
Prete SD; Montella L; Caraglia M; Maiorino L; Cennamo G; Montesarchio V; Piai G; Febbraro A; Tarantino L; Capasso E; Palmieri G; Guarrasi R; Bianco M; Mamone R; Savastano C; Pisano A; Vincenzi B; Sabia A; D'Agostino A; Faiola V; Addeo R
Cancer Chemother Pharmacol; 2010 Oct; 66(5):837-44. PubMed ID: 20041325
[TBL] [Abstract][Full Text] [Related]
9. Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma.
Attia S; Holen KD; Thomas JP; Richie K; Dzelak T; Teeter K; Warren D; Bilger A; Fine J; Eickhoff J; Drinkwater N; Mulkerin D; Morgan-Meadows S
Clin Adv Hematol Oncol; 2008 Jan; 6(1):44-54. PubMed ID: 18322441
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage.
Plentz RR; Tillmann HL; Kubicka S; Bleck JS; Gebel M; Manns MP; Rudolph KL
J Gastroenterol Hepatol; 2005 Sep; 20(9):1422-8. PubMed ID: 16105131
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience.
Montella L; Addeo R; Caraglia M; Faiola V; Guarrasi R; Vincenzi B; Palmeri A; Capasso E; Nocera V; Tarantino L; Ariete M; Martorelli A; Del Prete S
Oncol Rep; 2008 Aug; 20(2):385-90. PubMed ID: 18636202
[TBL] [Abstract][Full Text] [Related]
12. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial.
Chow PK; Tai BC; Tan CK; Machin D; Win KM; Johnson PJ; Soo KC;
Hepatology; 2002 Nov; 36(5):1221-6. PubMed ID: 12395333
[TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study.
Liu CL; Fan ST; Ng IO; Lo CM; Poon RT; Wong J
Am J Gastroenterol; 2000 Jan; 95(1):218-22. PubMed ID: 10638587
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.
Butturini G; Bettini R; Missiaglia E; Mantovani W; Dalai I; Capelli P; Ferdeghini M; Pederzoli P; Scarpa A; Falconi M
Endocr Relat Cancer; 2006 Dec; 13(4):1213-21. PubMed ID: 17158766
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.
Kouroumalis E; Skordilis P; Thermos K; Vasilaki A; Moschandrea J; Manousos ON
Gut; 1998 Mar; 42(3):442-7. PubMed ID: 9577356
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hepatocellular carcinoma with long acting somatostatin analogues.
Samonakis DN; Moschandreas J; Arnaoutis T; Skordilis P; Leontidis C; Vafiades I; Kouroumalis E
Oncol Rep; 2002; 9(4):903-7. PubMed ID: 12066229
[TBL] [Abstract][Full Text] [Related]
17. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma.
Bajetta E; Procopio G; Ferrari L; Martinetti A; Zilembo N; Catena L; Alú M; Della TS; Alberti D; Buzzoni R
Cancer; 2002 Jan; 94(2):299-304. PubMed ID: 11900215
[TBL] [Abstract][Full Text] [Related]
18. [Somatostatin analogue (octreotide)].
Sano K; Makuuchi M
Nihon Rinsho; 2001 Oct; 59 Suppl 6():674-7. PubMed ID: 11762035
[No Abstract] [Full Text] [Related]
19. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy.
Dickinson AJ; Vaidya B; Miller M; Coulthard A; Perros P; Baister E; Andrews CD; Hesse L; Heverhagen JT; Heufelder AE; Kendall-Taylor P
J Clin Endocrinol Metab; 2004 Dec; 89(12):5910-5. PubMed ID: 15579735
[TBL] [Abstract][Full Text] [Related]
20. [Octreotide in the treatment of advanced pancreatic tumor. Preliminary study].
Cirillo F; Bottini A; Brunelli A; Zuffada S; Bassi M; Filippini L; Alquati P
Minerva Chir; 1998 Dec; 53(12):979-85. PubMed ID: 10210927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
